George S, Carrico J, Hicks KA, Loukov D, Ng C, Regan J, Giannelos N. Updated public health impact and cost effectiveness of recombinant zoster vaccine in Canadian adults aged 50 years and older. Pharmacoecon Open. 2024 May;8(3):481-92. doi: 10.1007/s41669-024-00483-w
Pesantez D, Hoorn ST, Machado I, Garcia-Albeniz X, Rodriguez-Salas N, Heredia-Soto V, Vinal D, Pericay C, Garcia-Carbonero R, Losa F, Alonso V, Vera R, Batlle JF, Gallego J, Salud A, Nogue M, Layos L, Montagut C, Capdevila J, Vermeulen L, Maurel J, Fernandez-Martos C. Total neoadjuvant therapy with or without aflibercept in rectal cancer: three-year results of GEMCAD-1402. J Natl Cancer Inst. 2023 Dec 6;115(12):1497-505. doi: 10.1093/jnci/djad120
Salem A, La EM, Curran D, Patterson BJ, Carrico J, Lorenc S, Hicks KA, Poston S, Carpenter CF. Cost-effectiveness of recombinant zoster vaccine for the prevention of herpes zoster in hematopoietic stem cell transplant recipients and other immunocompromised adults in the United States. Pharmacoecon Open. 2023 Nov;7(6):975-85. doi: 10.1007/s41669-023-00438-7
Russell-Smith TA, Brockbank J, Mamolo C, Knight C. Cost effectiveness of gemtuzumab ozogamicin in the first-line treatment of acute myeloid leukaemia in the UK. Pharmacoecon Open. 2021 Dec;5(4):677-91. doi: 10.1007/s41669-021-00278-3
Garbinsky D, Hunter S, La EM, Poston S, Hogea C. State-level variations and factors associated with adult vaccination coverage: a multilevel modeling approach. Pharmacoecon Open. 2021 Sep;5(3):411-23. doi: 10.1007/s41669-021-00262-x
Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4
Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X, Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF oncogene expression and breast cancer bone metastasis. J Natl Cancer Inst. 2015 Sep 15;107(12):djv256. doi: 10.1093/jnci/djv256
Mehta RS, Song M, Bezawada N, Wu K, Garcia-Albeniz X, Morikawa T, Fuchs CS, Ogino S, Giovannucci EL, Chan AT. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J Natl Cancer Inst. 2014 Apr;106(4):dju016. doi: 10.1093/jnci/dju016
Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.
Lash TL, Fox MP, Greenland S, Jurek AM, Hoggatt KJ, Cole SR, Maldonado G, Brooks D, Rothman KJ, Poole C. Re: promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst. 2010 Jun 2;102(11):829-30. doi: 10.1093/jnci/djq135
Lash TL, Fox MP, Greenland S, Jurek AM, Hoggatt KJ, Cole SR, Maldonado G, Brooks D, Rothman KJ, Poole C. Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst. 2010 Jun;101(23):1596-9.
Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. The impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8.
Rothman KJ, MacMahon B, Lin TM, Lowe CR, Mirra AP, Ravnihar B, Salber EJ, Trichopoulos D, Yuasa S. Maternal age and birth rank of women with breast cancer. J Natl Cancer Inst. 1980 Oct;65(4):719-22.
Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst. 1977 Jan 1;59(4):1055-60.